{
    "pmcid": "9656363",
    "qa_pairs": {
        "What advantage do nanobodies have over conventional antibodies?": [
            "High affinity, stability, solubility, tissue penetration, and low production costs",
            "Larger size, higher production costs, and limited tissue penetration",
            "Lower affinity, reduced stability, and higher solubility",
            "Increased complexity, higher production costs, and limited epitope recognition"
        ],
        "What is the primary target for vaccines, neutralizing antibodies, and diagnostic tools in SARS-CoV-2?": [
            "The spike (S) protein of SARS-CoV-2",
            "The nucleocapsid (N) protein of SARS-CoV-2",
            "The membrane (M) protein of SARS-CoV-2",
            "The envelope (E) protein of SARS-CoV-2"
        ],
        "What limitation was observed in the binding of the identified nanobodies to SARS-CoV-2 variants?": [
            "Reduced binding to the Omicron variant",
            "Increased binding to the Delta variant",
            "No binding to the Alpha variant",
            "Enhanced binding to the Beta variant"
        ],
        "What was the size of the phage display library constructed by immunizing a camel with the SARS-CoV-2 RBD protein?": [
            "4.7 \u00d7 10^8 CFU",
            "3.5 \u00d7 10^8 CFU",
            "5.2 \u00d7 10^8 CFU",
            "6.1 \u00d7 10^8 CFU"
        ],
        "Which nanobody demonstrated the highest binding affinity for the SARS-CoV-2 S-RBD?": [
            "Nb61",
            "Nb25",
            "Nb52",
            "Nb68"
        ]
    }
}